[Elranatamab monotherapy in multiple myeloma after at least three prior treatments]

Bull Cancer. 2024 Oct;111(10):909-910. doi: 10.1016/j.bulcan.2024.06.006. Epub 2024 Sep 2.

[Article in French]

Authors

Erwann Collomb¹, Carolyne Croizier²

Affiliations

¹ Service d'hématologie et de thérapie cellulaire, hôpital de la Conception, AP-HM, Marseille, France.
² EA 7453 CHELTER, service d'hématologie clinique adulte et de thérapie cellulaire, CHU Estaing, université Clermont Auvergne, Clermont-Ferrand, France. Electronic address: ccroizier@chu-clermontferrand.fr.

PMID: 39227195
DOI: 10.1016/j.bulcan.2024.06.006

No abstract available

Keywords: Anticorps bispécifique; BCMA; Bispecific T-cell engager; Multiple myeloma; Myélome multiple; Rechute; Relapse.

Publication types

Letter
News

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Antibodies, Monoclonal, Humanized* / therapeutic use
Antineoplastic Agents / adverse effects
Antineoplastic Agents / therapeutic use
Humans
Multiple Myeloma* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents